1,000 patients join hunt for stomach cancer early warning signs
NCT ID NCT05021029
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study follows 1,000 people with stomach pre-cancer conditions like chronic gastritis and intestinal metaplasia. Researchers will track disease progression over time and analyze biospecimens to find biomarkers linked to cancer development. The goal is to better understand who is at risk and why, without testing any new treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help identify biomarkers that predict which patients are at highest risk of developing stomach cancer, enabling earlier intervention.
- What could go wrong
- This is an observational study, not a treatment trial. It may not directly lead to new therapies, and results may take years to translate into clinical practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATROPHIC GASTRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple test could spot who will develop stomach cancer
- Herbal granules take on a stomach condition that raises cancer risk
- New gastritis pill faces off against standard treatment in 470-Patient trial
- AI to predict cancer risk from gut bacteria and scans
- Tiny plastics, big danger? new study probes link to stomach cancer
- Could one pill a day replace three for stomach upset?